Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03083808
Title Phase II Trial of Continuation Therapy in Advanced NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greg Durm
Indications

lung non-small cell carcinoma

Therapies

Gemcitabine + Pembrolizumab

Docetaxel + Pembrolizumab

Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.